View Older Stories

May 7, 2026 09:25AM Lexaria Bioscience Releases Second Episode of Investor Video Series

May 5, 2026 09:11AM Lexaria advances human study testing oral semaglutide formulations

May 5, 2026 09:10AM Lexaria Updates Progress on Human Study #7

May 1, 2026 09:25AM Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Apr 29, 2026 09:10AM Lexaria extends pharmaceutical partnership through december 2026

Apr 29, 2026 09:10AM Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Apr 23, 2026 09:05AM Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Apr 21, 2026 09:10AM Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Apr 15, 2026 09:10AM Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Apr 7, 2026 09:10AM Lexaria notes FDA approval of Eli Lilly's oral weight-loss drug Foundayo

Apr 7, 2026 09:10AM Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 1, 2026 09:20AM Lexaria signs contracts for human study of oral semaglutide formulation

Apr 1, 2026 09:20AM Lexaria to Begin New Human Clinical Study in GLP-1

Mar 26, 2026 09:20AM Lexaria receives 5 new patents including diabetes and hypertension treatments

Mar 26, 2026 09:20AM Lexaria's Robust Patent Portfolio Continues to Grow

Mar 24, 2026 09:15AM Lexaria in talks with pharma companies for oral GLP-1 drug development

Mar 24, 2026 09:15AM Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 4, 2026 09:25AM Lexaria Bioscience plans three studies for drug delivery research

Mar 4, 2026 09:25AM Lexaria Announces New R&D Plans for 2026

Feb 5, 2026 09:15AM Lexaria Announces Positive Final Results From Human Pilot Study #5

Jan 22, 2026 09:22AM Lexaria receives six new patents, bringing total to 60 worldwide

Jan 22, 2026 09:20AM Lexaria Awarded Six Additional Patents

Jan 12, 2026 09:10AM Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Jan 12, 2026 09:10AM Lexaria Releases Annual Letter from the CEO

Dec 30, 2025 09:20AM Lexaria reports additional Phase 1b study results for drug delivery platform

Dec 30, 2025 09:20AM Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 29, 2025 05:13PM Lexaria Bioscience (LEXX) files for 2.75M share offering by selling stockholders

Dec 26, 2025 06:42AM Lexaria Bioscience (LEXX) PT Lowered to $1.50 at H.C. Wainwright

Dec 23, 2025 09:29AM Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Dec 23, 2025 09:29AM Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025 04:00PM Lexaria Bioscience closes $3.5 million registered direct offering

Dec 16, 2025 04:00PM Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025 08:01AM Lexaria Bioscience raises $3.5 million in registered direct offering

Dec 15, 2025 08:00AM Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 5, 2025 04:03PM Lexaria Bioscience (LEXX) files for 2.76M share offering by selling stockholders

Nov 12, 2025 09:11AM Lexaria extends pharmaceutical partnership agreement through April 2026

Nov 12, 2025 09:10AM Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Oct 9, 2025 09:20AM Lexaria Bioscience hires advisory firm, receives 4 new patents

Oct 9, 2025 09:20AM Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025 04:30PM Lexaria Bioscience closes $4 million registered direct offering

Sep 29, 2025 04:30PM Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025 08:00AM Lexaria Bioscience raises $4 million in registered direct offering

Sep 26, 2025 08:00AM Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025 11:25AM Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH

Sep 19, 2025 11:20AM Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 27, 2025 09:20AM Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025 09:20AM Lexaria completes patient dosing in Phase 1b GLP-1 study

Aug 14, 2025 09:20AM Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025 09:20AM GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 29, 2025 06:41AM Lexaria Bioscience (LEXX) PT Lowered to $4 at H.C. Wainwright

View Older Stories